Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

Fintel reports that on June 10, 2025, B of A Securities downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from ...

Naim Alkhouri, MD, FAASLD, DABOM, Chief Academic Officer, Summit Clinical Research, & Director of the Steatotic Liver Program, North Shore Gastroenterology, Cleveland, OH. A live question and answer ...

Curadev Pharma, Inc., a clinical-stage biotechnology company developing novel immuno-oncology therapeutics, and Memorial Sloan Kettering Cancer Center (MSK), a world-leading cancer research and ...

Shift Bioscience (Shift), a biotechnology company uncovering the biology of cell rejuvenation to develop new therapies for ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Ph.D., Chief Executive Officer, and Madhav Vasanthavada, Ph.D., Chief Commercial Officer, will participate in a fireside ...

Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell ...

Lineage Cell Therapeutics LCTX will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Lineage Cell ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX), with a market capitalization of $114 million, reported today that it has successfully completed a production run for two different product candidates ...

CEO of BrainStorm Cell Therapeutics. "We are optimistic about a rapid review and are eager to initiate our Phase 3b study, which we are undertaking to support regulatory approval." The Phase 3b ...